Merck said its ROTATEQ(Rotavirus Vaccine, Live, Oral, Pentavalent) received the Prix Galien USA 2010 Award for Best Biotechnology Product. Dr. Peter S. Kim, president of Merck Research Laboratories, commented, “We are honored that Merck’s long-term commitment to the discovery and development of new, innovative ways to prevent and treat disease is being acknowledged with this prestigious award. We congratulate the teams whose hard work and dedication contributed to ROTATEQ.” The Prix Galien recognizes the pharmaceutical industry’s outstanding achievement in the development of new medicines. The award was presented at a ceremony in New York City on 28 September 2010.
Prix Galien USA site: http://www.prix-galien-usa.com/
vaccines and global health :: ethics and policy 